News
The FDA has approved a dihydroergotamine-based nasal powder for the acute treatment of migraine with or without aura in ...
Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.
60-count bottle Propafenone hydrochloride extended-release capsules 325 mg, 60-count bottle Solifenacin succinate tablets 10 mg, 30-count bottle and 90-count bottle Voriconazole tablets 200 mg ...
Lupin gains US FDA approval for Tolvaptan tablets in various dosages, marking a significant entry into the nephrology market.
and Gabapentin tablets 600 mg (used to treat partial seizures, nerve pain from shingles and restless leg syndrome). The majority of the drugs were prescription only, meaning that most people ...
4d
MedPage Today on MSNNasal Powder for Acute Migraine Gets FDA NodThe FDA approved dihydroergotamine (DHE) nasal powder (Atzumi) 5.2 mg to treat acute migraine with or without aura in adults, ...
This may lead to increased levels of this drug in your blood. Your doctor will likely give you a starting dosage of 5 mg once daily. For people with kidney disease: Kidney disease can cause the ...
Net advances grow 1.4% to Rs 3.47 lakh crore Vs Rs 3.43 lakh crore Deposits increase 6.8% to Rs 4.11 lakh crore Vs Rs 3.84 lakh crore The GMV (gross merchandise value) growth for beauty vertical ...
When taken by mouth: Lutein is likely safe when taken by mouth. Consuming up to 20 mg of lutein daily as part of the diet or as a supplement appears to be safe.
New Delhi: MSN Laboratories has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to manufacture and market Lurasidone ...
The drug, available in 40 mg tablets, is approved as a new treatment for adults with erosive esophagitis of all grades. FEXUCLUE, containing Fexuprazan, is primarily used to treat acid-related ...
The Mumbai-based drug major, in a statement, said it has launched Fexuprazan tablets (40 mg) in India under the brand name Fexuclue, a novel potassium-competitive acid blocker (PCAB). The product is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results